

Date of Submission: 06<sup>th</sup> November 2017

|                                                                                                                                                                                        |                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br>Secretary<br>Listing Department<br>BSE Limited<br>Department of Corporate Services<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai – 400 001<br><b>Scrip Code - 539551</b> | To<br>Secretary<br>Listing Department<br>National Stock Exchange of India Limited<br>Exchange Plaza, Bandra Kurla Complex<br>Mumbai – 400 050<br><b>Stock Code- NH</b> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir/Madam,

**Sub: Outcome of Board meeting held on 06<sup>th</sup> November 2017.****Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR).**


With reference to the captioned subject, we wish to inform you that:

1. The meeting of Board of Directors commenced at 2.00 p.m and concluded at 7.00 p.m
2. The unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30<sup>th</sup> September, 2017 together with limited review report has been reviewed by Audit, Risk and Compliance Committee and considered and approved by the Board of Directors. In this regard, please find enclosed the unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30<sup>th</sup> September, 2017 together with limited review report.
3. Publication of results in Newspapers is being done as required under the SEBI LODR Regulations, 2015.

Kindly take the above said information on record as per the requirement of Listing Regulations.

Thanking You,

Yours faithfully

**For NARAYANA HRUDAYALAYA LIMITED**  
Sridhar S.

Group Company Secretary, Legal and Compliance Officer

Encl: A/A

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Narayana Hrudayalaya Limited

1. We have reviewed the accompanying Statement of Standalone Financial Results of **Narayana Hrudayalaya Limited** ("the Company"), for the quarter and six months ended September 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



V. Balaji  
Partner

Membership No. 203685

Narayana Hrudayalaya Limited  
Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India  
Corporate Office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India  
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@nhhospitals.org

**STATEMENT OF STANDALONE BALANCESHEET AS AT 30 SEPTEMBER 2017**

|           |                                           | (₹ in lakhs)                           |                                  |
|-----------|-------------------------------------------|----------------------------------------|----------------------------------|
| Sl. No.   | Particulars                               | As at 30 September 2017<br>(Unaudited) | As at 31 March 2017<br>(Audited) |
| <b>A.</b> | <b>ASSETS</b>                             |                                        |                                  |
| <b>1.</b> | <b>Non-current assets</b>                 |                                        |                                  |
| a)        | Property, plant and equipment             | 74,378.49                              | 67,986.84                        |
| b)        | Capital work-in-progress                  | 19,283.32                              | 5,157.43                         |
| c)        | Intangible assets                         | 202.71                                 | 259.03                           |
| d)        | Financial assets                          |                                        |                                  |
| i)        | Investments                               | 37,838.52                              | 35,399.60                        |
| ii)       | Loans                                     | 4,366.86                               | 3,845.70                         |
| iii)      | Other financial assets                    | 6.54                                   | 299.54                           |
| e)        | Income tax assets (net)                   | 974.60                                 | 1,297.20                         |
| f)        | Other non-current assets                  | 5,561.21                               | 5,832.94                         |
|           | <b>Sub-total- Non-current assets</b>      | <b>142,612.25</b>                      | <b>120,078.28</b>                |
| <b>2.</b> | <b>Current assets</b>                     |                                        |                                  |
| a)        | Inventories                               | 5,530.94                               | 4,343.82                         |
| b)        | Financial assets                          |                                        |                                  |
| i)        | Trade receivables                         | 17,058.89                              | 13,761.59                        |
| ii)       | Cash and cash equivalents                 | 1,262.26                               | 2,069.91                         |
| iii)      | Bank balances other than (ii) above       | 779.70                                 | 745.80                           |
| iv)       | Loans                                     | 798.31                                 | 1,779.75                         |
| v)        | Other financial assets                    | 1,930.02                               | 3,848.71                         |
| c)        | Other current assets                      | 2,915.94                               | 1,978.82                         |
|           | <b>Sub-total- Current assets</b>          | <b>30,276.06</b>                       | <b>28,528.40</b>                 |
|           | <b>TOTAL- ASSETS</b>                      | <b>172,888.31</b>                      | <b>148,606.68</b>                |
| <b>B.</b> | <b>EQUITY AND LIABILITIES</b>             |                                        |                                  |
| <b>1.</b> | <b>Equity</b>                             |                                        |                                  |
| a)        | Equity share capital                      | 20,436.08                              | 20,436.08                        |
| b)        | Other equity                              | 89,307.19                              | 85,411.10                        |
|           | <b>Sub-total- Total equity</b>            | <b>109,743.27</b>                      | <b>105,847.18</b>                |
| <b>2.</b> | <b>Non-current liabilities</b>            |                                        |                                  |
| a)        | Financial liabilities                     |                                        |                                  |
| i)        | Borrowings                                | 24,724.08                              | 9,570.32                         |
| ii)       | Other financial liabilities               | 610.55                                 | 591.93                           |
| b)        | Provisions                                | 1,238.82                               | 1,434.24                         |
| c)        | Deferred tax liabilities (net)            | 3,021.83                               | 2,296.51                         |
| d)        | Other non-current liabilities             | 2,024.55                               | 2,047.73                         |
|           | <b>Sub-total- Non-current liabilities</b> | <b>31,619.83</b>                       | <b>15,940.73</b>                 |
| <b>3.</b> | <b>Current liabilities</b>                |                                        |                                  |
| a)        | Financial liabilities                     |                                        |                                  |
| i)        | Borrowings                                | 553.33                                 | 448.82                           |
| ii)       | Trade payables                            | 22,357.88                              | 15,388.77                        |
| iii)      | Other financial liabilities               | 4,700.33                               | 7,847.76                         |
| b)        | Other current liabilities                 | 2,041.44                               | 2,043.78                         |
| c)        | Provisions                                | 1,872.23                               | 1,089.64                         |
|           | <b>Sub-total- Current liabilities</b>     | <b>31,525.21</b>                       | <b>26,818.77</b>                 |
|           | <b>TOTAL- EQUITY AND LIABILITIES</b>      | <b>172,888.31</b>                      | <b>148,606.68</b>                |



**Narayana Hrudayalaya Limited**

Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India  
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India  
CIN : L85110KA2000PLC027497, Website : www.narayanahealth.org, Email: investorrelations@nhhospitals.org

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2017**

|         |                                                                                                              | (₹ in lakhs, except per share data) |                               |                  |                  |                  |                   |
|---------|--------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------|------------------|------------------|------------------|-------------------|
| Sl. No. | Particulars                                                                                                  | Quarter ended                       |                               |                  | Half year ended  |                  | Year ended        |
|         |                                                                                                              | 30-Sep-17                           | 30-Jun-17                     | 30-Sep-16        | 30-Sep-17        | 30-Sep-16        | 31-Mar-17         |
|         |                                                                                                              | (Unaudited)                         | (Unaudited)<br>(refer note 5) | (Unaudited)      | (Unaudited)      | (Unaudited)      | (Audited)         |
| 1.      | <b>Income</b>                                                                                                |                                     |                               |                  |                  |                  |                   |
|         | (a) Revenue from operations                                                                                  | 46,901.24                           | 44,109.31                     | 42,593.37        | 91,010.55        | 82,637.78        | 164,591.44        |
|         | (b) Other income                                                                                             | 476.20                              | 500.56                        | 462.06           | 976.76           | 768.44           | 1,814.62          |
|         | <b>Total income</b>                                                                                          | <b>47,377.44</b>                    | <b>44,609.87</b>              | <b>43,055.43</b> | <b>91,987.31</b> | <b>83,406.22</b> | <b>166,406.06</b> |
| 2.      | <b>Expenses</b>                                                                                              |                                     |                               |                  |                  |                  |                   |
|         | (a) Purchases of medical consumables, drugs and surgical equipments                                          | 10,232.37                           | 13,148.20                     | 10,468.39        | 23,380.57        | 20,223.84        | 38,655.06         |
|         | (b) Changes in inventories of medical consumables, drugs and surgical equipments                             | 1,192.15                            | (2,379.27)                    | (347.64)         | (1,187.12)       | (442.03)         | 47.35             |
|         | (c) Employee benefits expenses                                                                               | 9,326.42                            | 9,240.22                      | 8,429.12         | 18,566.64        | 16,528.50        | 32,982.97         |
|         | (d) Professional fees to doctors                                                                             | 9,596.79                            | 9,153.83                      | 8,201.34         | 18,750.62        | 16,069.75        | 32,741.68         |
|         | (e) Other expenses                                                                                           | 11,547.37                           | 10,469.40                     | 10,027.37        | 22,016.77        | 19,414.12        | 38,925.79         |
|         | <b>Total expenses</b>                                                                                        | <b>41,895.10</b>                    | <b>39,632.38</b>              | <b>36,778.58</b> | <b>81,527.48</b> | <b>71,794.18</b> | <b>143,352.85</b> |
| 3.      | <b>Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)</b>     | <b>5,482.34</b>                     | <b>4,977.49</b>               | <b>6,276.85</b>  | <b>10,459.83</b> | <b>11,612.04</b> | <b>23,053.21</b>  |
| 4.      | Finance costs                                                                                                | 387.08                              | 456.92                        | 273.44           | 844.00           | 562.18           | 1,180.82          |
| 5.      | Depreciation and amortisation expense                                                                        | 2,110.34                            | 1,797.50                      | 1,677.99         | 3,907.84         | 3,280.16         | 6,820.57          |
| 6.      | <b>Profit before tax and exceptional items (3-4-5)</b>                                                       | <b>2,984.92</b>                     | <b>2,723.07</b>               | <b>4,325.42</b>  | <b>5,707.99</b>  | <b>7,769.70</b>  | <b>15,051.82</b>  |
| 7.      | Exceptional items (refer note 2)                                                                             | 115.76                              | -                             | -                | 115.76           | -                | 319.08            |
| 8.      | <b>Profit before tax (6-7)</b>                                                                               | <b>2,869.16</b>                     | <b>2,723.07</b>               | <b>4,325.42</b>  | <b>5,592.23</b>  | <b>7,769.70</b>  | <b>14,732.74</b>  |
| 9.      | Tax expense                                                                                                  | 964.36                              | 1,005.61                      | 1,457.04         | 1,969.97         | 2,636.20         | 5,221.85          |
| 10.     | <b>Profit for the period/ year (8-9)</b>                                                                     | <b>1,904.80</b>                     | <b>1,717.46</b>               | <b>2,868.38</b>  | <b>3,622.26</b>  | <b>5,133.50</b>  | <b>9,510.89</b>   |
| 11.     | <b>Other comprehensive income</b>                                                                            |                                     |                               |                  |                  |                  |                   |
|         | <i>Items that will not be reclassified subsequently to profit or loss</i>                                    |                                     |                               |                  |                  |                  |                   |
|         | (a) Re-measurement gains/(losses) on defined benefit plans                                                   | 2.82                                | 29.83                         | (16.47)          | 32.65            | 106.71           | 57.63             |
|         | (b) Income tax effect                                                                                        | (1.04)                              | (10.26)                       | 5.70             | (11.30)          | (36.93)          | (19.62)           |
|         | <b>Other comprehensive income, net of taxes</b>                                                              | <b>1.78</b>                         | <b>19.57</b>                  | <b>(10.77)</b>   | <b>21.35</b>     | <b>69.78</b>     | <b>38.01</b>      |
| 12.     | <b>Total comprehensive income (10+11)</b>                                                                    | <b>1,906.58</b>                     | <b>1,737.03</b>               | <b>2,857.61</b>  | <b>3,643.61</b>  | <b>5,203.28</b>  | <b>9,548.90</b>   |
| 13.     | Paid-up equity share capital<br>(Face value of ₹ 10 each)                                                    | 20,436.08                           | 20,436.08                     | 20,436.08        | 20,436.08        | 20,436.08        | 20,436.08         |
| 14.     | Reserve excluding revaluation reserves i.e. 'Other Equity' as per balance sheet of previous accounting year. | -                                   | -                             | -                | -                | -                | 85,411.10         |
| 15.     | Earnings per share<br>(of ₹ 10 each) :                                                                       | not annualised                      | not annualised                | not annualised   | not annualised   | not annualised   | annualised        |
|         | (a) Basic                                                                                                    | 0.94                                | 0.85                          | 1.42             | 1.79             | 2.54             | 4.70              |
|         | (b) Diluted                                                                                                  | 0.94                                | 0.85                          | 1.41             | 1.79             | 2.53             | 4.69              |
|         | See accompanying notes to the financial results                                                              |                                     |                               |                  |                  |                  |                   |



**Notes:**

1. The statement of standalone financial results ('the Statement') of Narayana Hrudayalaya Limited ('the Company') for the quarter and half year ended 30 September 2017 has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors on 06 November 2017.

The statement has been subjected to limited review by Deloitte Haskins & Sells LLP, the statutory auditor of the Company. The report of the statutory auditor is unqualified.

2. Exceptional item for the quarter and half year ended 30 September 2017 represents loss of ₹ 115.76 lakhs on impairment of investment in its associate "Trimedx India Private Limited".  
Also, exceptional item for the year ended 31 March 2017 represents loss of ₹ 319.08 lakhs on sale of its investment in wholly owned subsidiary "Asia Healthcare Development Limited" through a sale agreement dated 10 November 2016.
3. The Company's operating segment is 'Medical and Healthcare Services'. Since the Company has a single operating segment, disclosures pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.
4. Pursuant to the approval on 21 April 2017 by the Committee formed by the Board of Directors, the Company signed a Share Purchase Agreement ('SPA') and acquired 100% equity and preference shares in NewRise Healthcare Private Limited ('NewRise'), a wholly owned subsidiary of Panacea Biotech Limited for a consideration of ₹ 7,564 lakhs payable in cash. As per the SPA, the Company granted a loan of ₹ 10,329 lakhs to NewRise.

Further, as per the Order dated 04 October 2017 from MCA the merger of NewRise with the Company is approved under Section 233 of the Companies Act, 2013.

5. The appointed date of scheme being 01 July 2017, this a common control transaction under Ind AS, the merger is given effect retrospectively from 21 April 2017, the date of acquisition of NewRise. Consequently, the amounts for the quarter ended 30 June 2017 included in the Statement has been restated to give effect to the common control transaction. The key items in the results as previously reported are as under:

| (₹ in lakhs)      |                            |
|-------------------|----------------------------|
| Particulars       | Quarter ended<br>30-Jun-17 |
| Total income      | 44,779.18                  |
| Total expenses    | 39,582.99                  |
| Profit before tax | 2,942.91                   |

6. Ascension Health Ventures LLC, USA (AHV), an affiliate of Ascension Health Alliance, USA (AHA) holds 71.4% stake in Health City Cayman Islands Ltd (HCCI), an associate of Narayana Hrudayalaya Ltd (NHL) which through Narayana Cayman Holding Ltd (a wholly owned subsidiary of NHL) holds the balance 28.6%. The aforesaid parties have entered into a definitive agreement on 06 November 2017 whereby HCCI will buyback 71.4% stake from AHV for a consideration of US\$ 32.26 million. Consequent to this buyback, HCCI will become a wholly owned step down subsidiary of NHL. This transaction is expected to be completed by Quarter ending 31 March 2018.
7. Amounts for the quarters ended 30 June 2017 and 30 September 2016 and half year ended 30 September 2016 and year ended 31 March 2017 were reviewed/audited by the previous auditors - BSR& CO LLP.

for and on behalf of the Board of Directors of  
Narayana Hrudayalaya Limited

Place: Bengaluru  
Date : 06 November 2017



*Ashu tosh*

Dr. Ashutosh Raghuvanshi  
Managing Director

*Ashu tosh*  
*for*

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED

1. We have reviewed the accompanying Statement of Consolidated Financial Results of **NARAYANA HRUDAYALAYA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the loss of its associates for the quarter and half-year ended September 30, 2017 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:

| Sl. No. | Entity                                                    | Relationship |
|---------|-----------------------------------------------------------|--------------|
| 1.      | Narayana Hrudayalaya Limited                              | Parent       |
| 2.      | Narayana Institute for Advanced Research Private Limited  | Subsidiary   |
| 3.      | Narayana Hospitals Private Limited                        | Subsidiary   |
| 4.      | Narayana Health Institutions Private Limited              | Subsidiary   |
| 5.      | Meridian Medical Research & Hospital Limited              | Subsidiary   |
| 6.      | Narayana Vaishno Devi Specialty Hospitals Private Limited | Subsidiary   |
| 7.      | Narayana Hrudayalaya Surgical Hospital Private Limited    | Subsidiary   |
| 8.      | Narayana Cayman Holdings Limited                          | Subsidiary   |
| 9.      | Narayana Hrudayalaya Hospital Malaysia                    | Subsidiary   |
| 10.     | Narayana Holdings Private Limited                         | Subsidiary   |
| 11.     | Trimedx India Private Limited                             | Associate    |
| 12.     | Health City Cayman Island Limited                         | Associate    |
| 13.     | ISO Healthcare Limited (Mauritius)                        | Associate    |
| 14.     | CURA Technologies Inc                                     | Associate    |

✓

# Deloitte Haskins & Sells LLP

4. Based on our review conducted as stated above and based on the consideration of the review reports of the other auditors referred to in paragraph 5 below and read with our comments in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of three subsidiaries included in the consolidated financial results, whose interim financial results reflect total revenues of Rs. 9.41 lakhs and Rs. 15.93 lakhs for the quarter and half-year ended September 30, 2017 respectively, and total loss after tax of Rs. 33.23 lakhs and Rs. 300.78 lakhs and total comprehensive loss of Rs. 33.23 lakhs and Rs. 300.78 lakhs for the quarter and half-year ended September 30, 2017 respectively, as considered in the consolidated financial results. The consolidated financial results also include the Group's share of profit after tax of Rs. 118.20 lakhs and Rs. 0.93 lakhs for the quarter and half-year ended September 30, 2017 respectively, in respect of two associates, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. The consolidated financial results also includes the Group's share of loss after tax of Rs. 133.58 lakhs and Rs. 269.88 lakhs for the quarter and half-year ended September 30, 2017, in respect of one associate, based on their interim financial results which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our report on the Statement is not modified in respect of our reliance on the interim financial results certified by the Management.

**For DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



V. Balaji  
Partner

Membership No. 203685

Place: Bengaluru  
Date: November 6, 2017

Narayana Hrudayalaya Limited  
Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 562 158, Karnataka, India  
Corporate Office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 562 158, Karnataka, India  
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@nhhospitals.org

STATEMENT OF CONSOLIDATED BALANCE SHEET AS AT 30 SEPTEMBER 2017

|           |                                                           | (₹ in lakhs)                           |                                  |
|-----------|-----------------------------------------------------------|----------------------------------------|----------------------------------|
| Sl. No.   | Particulars                                               | As at 30 September 2017<br>(Unaudited) | As at 31 March 2017<br>(Audited) |
| <b>A.</b> | <b>ASSETS</b>                                             |                                        |                                  |
| 1.        | <b>Non- current assets</b>                                |                                        |                                  |
| a)        | Property, plant and equipment                             | 111,668.10                             | 102,094.57                       |
| b)        | Capital work-in-progress                                  | 19,314.36                              | 5,303.56                         |
| c)        | Goodwill                                                  | 5,814.74                               | 5,814.74                         |
| d)        | Other intangible assets                                   | 7,701.90                               | 269.21                           |
| e)        | Equity accounted investees                                | 9,583.27                               | 9,282.83                         |
| f)        | Financial assets                                          |                                        |                                  |
| i)        | Investments                                               | 364.46                                 | 325.40                           |
| ii)       | Loans                                                     | 2,810.90                               | 2,025.61                         |
| iii)      | Other financial assets                                    | 8.46                                   | 200.02                           |
| g)        | Income tax assets (net)                                   | 1,727.12                               | 1,987.47                         |
| h)        | Other non-current assets                                  | 6,169.91                               | 7,218.06                         |
|           | <b>Non-current assets</b>                                 | <b>165,163.22</b>                      | <b>134,521.47</b>                |
| 2.        | <b>Current assets</b>                                     |                                        |                                  |
| a)        | Inventories                                               | 6,615.87                               | 5,235.97                         |
| b)        | Financial assets                                          |                                        |                                  |
| i)        | Trade receivables                                         | 20,396.55                              | 15,691.01                        |
| ii)       | Cash and cash equivalents                                 | 1,867.43                               | 2,624.29                         |
| iii)      | Bank balances other than (ii) above                       | 830.23                                 | 787.75                           |
| iv)       | Loans                                                     | 359.17                                 | 300.72                           |
| v)        | Other financial assets                                    | 2,433.91                               | 3,527.08                         |
| c)        | Other current assets                                      | 3,615.17                               | 1,991.18                         |
|           | <b>Current assets</b>                                     | <b>36,118.33</b>                       | <b>30,158.00</b>                 |
|           | <b>TOTAL- ASSETS</b>                                      | <b>201,281.55</b>                      | <b>164,679.47</b>                |
| <b>B.</b> | <b>EQUITY AND LIABILITIES</b>                             |                                        |                                  |
| 1.        | <b>Equity</b>                                             |                                        |                                  |
| a)        | Equity share capital                                      | 20,436.08                              | 20,436.08                        |
| b)        | Other equity                                              | 78,970.84                              | 75,872.10                        |
|           | <b>Total equity attributable to owners of the Company</b> | <b>99,406.92</b>                       | <b>96,308.18</b>                 |
| 2.        | <b>Non-controlling interests</b>                          | 24.17                                  | 23.61                            |
|           | <b>Total equity</b>                                       | <b>99,431.09</b>                       | <b>96,331.79</b>                 |
| 3.        | <b>Non-current liabilities</b>                            |                                        |                                  |
| a)        | Financial liabilities                                     |                                        |                                  |
| i)        | Borrowings                                                | 29,092.20                              | 17,980.11                        |
| ii)       | Other financial liabilities                               | 12,204.94                              | 591.93                           |
| b)        | Provisions                                                | 1,394.96                               | 1,508.36                         |
| c)        | Deferred tax liabilities (net)                            | 3,205.64                               | 2,480.32                         |
| d)        | Other non-current liabilities                             | 13,401.62                              | 13,531.35                        |
|           | <b>Non-current liabilities</b>                            | <b>59,299.36</b>                       | <b>36,092.07</b>                 |
| 4.        | <b>Current liabilities</b>                                |                                        |                                  |
| a)        | Financial liabilities                                     |                                        |                                  |
| i)        | Borrowings                                                | 4,735.11                               | 902.22                           |
| ii)       | Trade payables                                            | 27,233.94                              | 18,854.60                        |
| iii)      | Other financial liabilities                               | 5,766.97                               | 8,731.33                         |
| b)        | Other current liabilities                                 | 2,817.85                               | 2,540.81                         |
| c)        | Provisions                                                | 1,992.90                               | 1,222.32                         |
| d)        | Income tax liabilities (net)                              | 4.33                                   | 4.33                             |
|           | <b>Current liabilities</b>                                | <b>42,551.10</b>                       | <b>32,255.61</b>                 |
|           | <b>TOTAL- EQUITY AND LIABILITIES</b>                      | <b>201,281.55</b>                      | <b>164,679.47</b>                |



Narayana Hrudayalaya Limited

Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560 099, Karnataka, India  
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560 099, Karnataka, India  
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@nhhospitals.org

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2017

| Sl. No. | Particulars                                                                                                  | (₹ in lakhs, except per share data) |                          |                          |                          |                          |                        |
|---------|--------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------|
|         |                                                                                                              | Quarter ended                       |                          |                          | Half year ended          |                          | Year ended             |
|         |                                                                                                              | 30-Sep-17<br>(Unaudited)            | 30-Jun-17<br>(Unaudited) | 30-Sep-16<br>(Unaudited) | 30-Sep-17<br>(Unaudited) | 30-Sep-16<br>(Unaudited) | 31-Mar-17<br>(Audited) |
| 1.      | <b>Income</b>                                                                                                |                                     |                          |                          |                          |                          |                        |
|         | (a) Revenue from operations                                                                                  | 55,916.35                           | 52,110.99                | 48,741.41                | 108,027.34               | 93,936.84                | 187,816.49             |
|         | (b) Other income                                                                                             | 571.11                              | 522.92                   | 475.40                   | 1,094.03                 | 786.36                   | 1,748.24               |
|         | <b>Total income</b>                                                                                          | <b>56,487.46</b>                    | <b>52,633.91</b>         | <b>49,216.81</b>         | <b>109,121.37</b>        | <b>94,723.20</b>         | <b>189,564.73</b>      |
| 2.      | <b>Expenses</b>                                                                                              |                                     |                          |                          |                          |                          |                        |
|         | (a) Purchase of medical consumables, drugs and surgical equipments                                           | 11,998.14                           | 15,373.81                | 12,054.23                | 27,371.95                | 22,952.50                | 43,887.90              |
|         | (b) Changes in inventories of medical consumables, drugs and surgical equipments                             | 1,547.68                            | (2,766.36)               | (654.79)                 | (1,218.68)               | (886.99)                 | (298.09)               |
|         | (c) Employee benefits expenses                                                                               | 10,948.20                           | 10,725.08                | 9,607.59                 | 21,673.28                | 18,755.18                | 37,521.05              |
|         | (d) Professional fees to doctors                                                                             | 11,648.79                           | 11,049.42                | 9,685.75                 | 22,698.21                | 18,893.21                | 38,557.35              |
|         | (e) Other expenses                                                                                           | 13,963.81                           | 12,688.67                | 11,713.93                | 26,652.48                | 22,607.46                | 45,262.74              |
|         | <b>Total expenses</b>                                                                                        | <b>50,106.62</b>                    | <b>47,070.62</b>         | <b>42,406.71</b>         | <b>97,177.24</b>         | <b>82,321.36</b>         | <b>164,930.95</b>      |
| 3.      | <b>Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)</b>     | <b>6,380.84</b>                     | <b>5,563.29</b>          | <b>6,810.10</b>          | <b>11,944.13</b>         | <b>12,401.84</b>         | <b>24,633.78</b>       |
| 4.      | Finance costs                                                                                                | 775.16                              | 1,030.96                 | 527.37                   | 1,806.12                 | 1,074.70                 | 2,180.34               |
| 5.      | Depreciation and amortisation expense                                                                        | 2,854.84                            | 2,181.64                 | 1,970.35                 | 5,036.48                 | 3,865.67                 | 7,992.08               |
| 6.      | <b>Profit before exceptional items (3-4-5)</b>                                                               | <b>2,750.84</b>                     | <b>2,350.69</b>          | <b>4,312.38</b>          | <b>5,101.53</b>          | <b>7,461.47</b>          | <b>14,461.36</b>       |
| 7.      | Exceptional items (refer note 2)                                                                             | 115.76                              | -                        | -                        | 115.76                   | -                        | 134.03                 |
| 8.      | <b>Profit before share of loss of equity accounted investees and income tax (6-7)</b>                        | <b>2,635.08</b>                     | <b>2,350.69</b>          | <b>4,312.38</b>          | <b>4,985.77</b>          | <b>7,461.47</b>          | <b>14,327.33</b>       |
| 9.      | Share of loss of equity accounted investees                                                                  | 15.38                               | 253.57                   | 204.16                   | 268.95                   | 445.71                   | 793.41                 |
| 10.     | <b>Profit before tax (8-9)</b>                                                                               | <b>2,619.70</b>                     | <b>2,097.12</b>          | <b>4,108.22</b>          | <b>4,716.82</b>          | <b>7,015.76</b>          | <b>13,533.92</b>       |
| 11.     | Tax expense                                                                                                  | 965.12                              | 1,004.85                 | 1,459.69                 | 1,969.97                 | 2,642.99                 | 5,236.61               |
| 12.     | <b>Profit for the period/ year (10-11)</b>                                                                   | <b>1,654.58</b>                     | <b>1,092.27</b>          | <b>2,648.53</b>          | <b>2,746.85</b>          | <b>4,372.77</b>          | <b>8,297.31</b>        |
| 13.     | <b>Other comprehensive income</b>                                                                            |                                     |                          |                          |                          |                          |                        |
|         | Items that will not be reclassified subsequently to profit or loss                                           |                                     |                          |                          |                          |                          |                        |
|         | (a) Re-measurement gains/(losses) on defined benefit plans                                                   | (33.22)                             | 25.28                    | (45.19)                  | (7.94)                   | 88.45                    | 23.07                  |
|         | (b) Income tax effect                                                                                        | (1.04)                              | (10.26)                  | 5.70                     | (11.30)                  | (36.93)                  | (19.62)                |
|         | <b>Other comprehensive income, net of taxes</b>                                                              | <b>(34.26)</b>                      | <b>15.02</b>             | <b>(39.49)</b>           | <b>(19.24)</b>           | <b>51.52</b>             | <b>3.45</b>            |
| 14.     | <b>Total comprehensive income (12+13)</b>                                                                    | <b>1,620.32</b>                     | <b>1,107.29</b>          | <b>2,609.04</b>          | <b>2,727.61</b>          | <b>4,424.29</b>          | <b>8,300.76</b>        |
| 15.     | <b>Profit attributable to:</b>                                                                               |                                     |                          |                          |                          |                          |                        |
|         | Owners of the company                                                                                        | 1,654.89                            | 1,093.86                 | 2,651.40                 | 2,748.75                 | 4,376.59                 | 8,305.21               |
|         | Non-controlling interests                                                                                    | (0.31)                              | (1.59)                   | (2.87)                   | (1.90)                   | (3.82)                   | (7.90)                 |
|         | <b>Profit for the period/ year</b>                                                                           | <b>1,654.58</b>                     | <b>1,092.27</b>          | <b>2,648.53</b>          | <b>2,746.85</b>          | <b>4,372.77</b>          | <b>8,297.31</b>        |
| 16.     | <b>Other comprehensive income attributable to:</b>                                                           |                                     |                          |                          |                          |                          |                        |
|         | Owners of the company                                                                                        | (34.40)                             | 15.45                    | (39.35)                  | (18.95)                  | 51.62                    | 3.75                   |
|         | Non-controlling interests                                                                                    | 0.14                                | (0.43)                   | (0.14)                   | (0.29)                   | (0.10)                   | (0.30)                 |
|         | <b>Other comprehensive income for the period/ year</b>                                                       | <b>(34.26)</b>                      | <b>15.02</b>             | <b>(39.49)</b>           | <b>(19.24)</b>           | <b>51.52</b>             | <b>3.45</b>            |
| 17.     | <b>Total comprehensive income attributable to:</b>                                                           |                                     |                          |                          |                          |                          |                        |
|         | Owners of the company                                                                                        | 1,620.49                            | 1,109.31                 | 2,612.05                 | 2,729.80                 | 4,428.21                 | 8,308.96               |
|         | Non-controlling interests                                                                                    | (0.17)                              | (2.02)                   | (3.01)                   | (2.19)                   | (3.92)                   | (8.20)                 |
|         | <b>Total comprehensive income for the period/ year (15+16)</b>                                               | <b>1,620.32</b>                     | <b>1,107.29</b>          | <b>2,609.04</b>          | <b>2,727.61</b>          | <b>4,424.29</b>          | <b>8,300.76</b>        |
| 18.     | Paid-up equity share capital<br>(Face value of ₹ 10 each)                                                    | 20,436.08                           | 20,436.08                | 20,436.08                | 20,436.08                | 20,436.08                | 20,436.08              |
| 19.     | Reserves excluding revaluation reserves i.e. 'Other Equity' as per balance sheet of previous accounting year | -                                   | -                        | -                        | -                        | -                        | 75,872.10              |
| 20.     | Earnings per share<br>(of ₹ 10 each):                                                                        | not annualised                      | not annualised           | not annualised           | not annualised           | not annualised           | annualised             |
|         | (a) Basic                                                                                                    | 0.82                                | 0.54                     | 1.31                     | 1.36                     | 2.16                     | 4.10                   |
|         | (b) Diluted                                                                                                  | 0.82                                | 0.54                     | 1.31                     | 1.36                     | 2.16                     | 4.09                   |
|         | See accompanying notes to the financial results                                                              |                                     |                          |                          |                          |                          |                        |



**Notes:**

- 1 The statement of consolidated financial results ('the Statement') of Narayana Hrudayalaya Limited ('the Company'), its subsidiaries and associates (collectively referred to as 'the Group') for the quarter ended and half year ended 30 September 2017 has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors on 6 November 2017.  
  
The statement has been subjected to limited review by Deloitte Haskins & Sells LLP, the statutory auditor of the Company. The report of the statutory auditor is unqualified.
- 2 Exceptional item for the quarter and half year ended 30 September 2017 represents loss of ₹ 115.76 lakhs on impairment of investment in its associate "Trimedx India Private Limited".  
Also, exceptional item for the year ended 31 March 2017 represents loss of ₹ 319.08 lakhs on sale of its investment in wholly owned subsidiary "Asia Healthcare Development Limited" through a sale agreement dated 10 November 2016.
- 3 The Group's operating segment is 'Medical and Healthcare Services'. Since the Group has a single operating segment, disclosures pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.
- 4 Pursuant to the approval on 21 April 2017 by the Committee formed by the Board of Directors, the Company signed a Share Purchase Agreement ('SPA') and acquired 100% equity and preference shares in NewRise Healthcare Private Limited ('NewRise'), a wholly owned subsidiary of Panacea Biotech Limited for a consideration of ₹ 7,564 lakhs payable in cash. As per the SPA, the Company granted a loan of ₹ 10,329 lakhs to NewRise.  
Further, as per the Order dated 04 October 2017 from MCA the merger of NewRise with the Company is approved under Section 233 of the Companies Act, 2013. The appointed date is 01 July 2017.
- 5 Ascension Health Ventures LLC, USA (AHV), an affiliate of Ascension Health Alliance, USA (AHA) holds 71.4% stake in Health City Cayman Islands Ltd (HCCI), an associate of Narayana Hrudayalaya Ltd (NHL) which through Narayana Cayman Holding Ltd ( a wholly owned subsidiary of NHL) holds the balance 28.6%. The aforesaid parties have entered into a definitive agreement on 06 November 2017 whereby HCCI will buyback 71.4% stake from AHV for a consideration of US\$ 32.26 million. Consequent to this buyback, HCCI will become a wholly owned step down subsidiary of NHL. This transaction is expected to be completed by Quarter ending 31 March 2018.
- 6 Amounts for the quarters ended 30 June 2017 and 30 September 2016 and half year ended 30 September 2016 and year ended 31 March 2017 were reviewed/audited by the previous auditors - BSR& CO LLP.

for and on behalf of the Board of Directors of  
Narayana Hrudayalaya Limited

*Ashutosh*

Dr. Ashutosh Raghuvanshi  
Managing Director

Place: Bengaluru

Date: 06 November 2017

